BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

76 related articles for article (PubMed ID: 8280137)

  • 1. Sequence specific binding of the transcription factor c-Ets1 to the human immunodeficiency virus type I long terminal repeat.
    Holzmeister J; Ludewig B; Pauli G; Simon D
    Biochem Biophys Res Commun; 1993 Dec; 197(3):1229-33. PubMed ID: 8280137
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Both PU.1 and nuclear factor-kappa B mediate lipopolysaccharide- induced HIV-1 long terminal repeat transcription in macrophages.
    Lodie TA; Reiner M; Coniglio S; Viglianti G; Fenton MJ
    J Immunol; 1998 Jul; 161(1):268-76. PubMed ID: 9647233
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cooperative interaction of ets-1 with USF-1 required for HIV-1 enhancer activity in T cells.
    Sieweke MH; Tekotte H; Jarosch U; Graf T
    EMBO J; 1998 Mar; 17(6):1728-39. PubMed ID: 9501094
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Regulatory elements involved in tax-mediated transactivation of the HTLV-I LTR.
    Seeler JS; Muchardt C; Podar M; Gaynor RB
    Virology; 1993 Oct; 196(2):442-50. PubMed ID: 8372429
    [TBL] [Abstract][Full Text] [Related]  

  • 5. FLI1 and EWS-FLI1 function as ternary complex factors and ELK1 and SAP1a function as ternary and quaternary complex factors on the Egr1 promoter serum response elements.
    Watson DK; Robinson L; Hodge DR; Kola I; Papas TS; Seth A
    Oncogene; 1997 Jan; 14(2):213-21. PubMed ID: 9010223
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Interaction of ETS-1 and ERGB/FLI-1 proteins with DNA is modulated by spacing between multiple binding sites as well as phosphorylation.
    Hodge DR; Robinson L; Watson D; Lautenberger J; Zhang XK; Venanzoni M; Seth A
    Oncogene; 1996 Jan; 12(1):11-8. PubMed ID: 8552380
    [TBL] [Abstract][Full Text] [Related]  

  • 7. U5 region of the human immunodeficiency virus type 1 long terminal repeat contains TRE-like cAMP-responsive elements that bind both AP-1 and CREB/ATF proteins.
    Rabbi MF; Saifuddin M; Gu DS; Kagnoff MF; Roebuck KA
    Virology; 1997 Jun; 233(1):235-45. PubMed ID: 9201233
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Stable co-occupancy of transcription factors and histones at the HIV-1 enhancer.
    Steger DJ; Workman JL
    EMBO J; 1997 May; 16(9):2463-72. PubMed ID: 9171359
    [TBL] [Abstract][Full Text] [Related]  

  • 9. ETS1, NFkappaB and AP1 synergistically transactivate the human GM-CSF promoter.
    Thomas RS; Tymms MJ; McKinlay LH; Shannon MF; Seth A; Kola I
    Oncogene; 1997 Jun; 14(23):2845-55. PubMed ID: 9190901
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Binding of ETS family members is important for the function of the c-sis/platelet-derived growth factor-B TATA neighboring sequence in 12-O-tetradecanoylphorbol-13-acetate-treated K562 cells.
    Kujoth GC; Robinson DF; Fahl WE
    Cell Growth Differ; 1998 Jul; 9(7):523-34. PubMed ID: 9690620
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Differential effects of I kappa B molecules on Tat-mediated transactivation of HIV-1 LTR.
    Harhaj E; Blaney J; Millhouse S; Sun SC
    Virology; 1996 Feb; 216(1):284-7. PubMed ID: 8615004
    [TBL] [Abstract][Full Text] [Related]  

  • 12. NF-kappaB-repressing factor inhibits elongation of human immunodeficiency virus type 1 transcription by DRB sensitivity-inducing factor.
    Dreikhausen U; Hiebenthal-Millow K; Bartels M; Resch K; Nourbakhsh M
    Mol Cell Biol; 2005 Sep; 25(17):7473-83. PubMed ID: 16107696
    [TBL] [Abstract][Full Text] [Related]  

  • 13. High-affinity DNA-protein interactions of the cellular ETS1 protein: the determination of the ETS binding motif.
    Fisher RJ; Mavrothalassitis G; Kondoh A; Papas TS
    Oncogene; 1991 Dec; 6(12):2249-54. PubMed ID: 1766672
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Transactivation of GATA-1 promoter with ETS1, ETS2 and ERGB/Hu-FLI-1 proteins: stabilization of the ETS1 protein binding on GATA-1 promoter sequences by monoclonal antibody.
    Seth A; Robinson L; Thompson DM; Watson DK; Papas TS
    Oncogene; 1993 Jul; 8(7):1783-90. PubMed ID: 8510925
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ets up-regulates MET transcription.
    Gambarotta G; Boccaccio C; Giordano S; Andŏ M; Stella MC; Comoglio PM
    Oncogene; 1996 Nov; 13(9):1911-7. PubMed ID: 8934537
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dual control of myc expression through a single DNA binding site targeted by ets family proteins and E2F-1.
    Roussel MF; Davis JN; Cleveland JL; Ghysdael J; Hiebert SW
    Oncogene; 1994 Feb; 9(2):405-15. PubMed ID: 8290253
    [TBL] [Abstract][Full Text] [Related]  

  • 17. BCL6 can repress transcription from the human immunodeficiency virus type I promoter/enhancer region.
    Baron BW; Desai M; Baber LJ; Paras L; Zhang Q; Sadhu A; Duguay S; Nucifora G; McKeithan TW; Zeleznik-Le N
    Genes Chromosomes Cancer; 1997 May; 19(1):14-21. PubMed ID: 9135990
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Analysis of the HIV-1 LTR NF-kappaB-proximal Sp site III: evidence for cell type-specific gene regulation and viral replication.
    McAllister JJ; Phillips D; Millhouse S; Conner J; Hogan T; Ross HL; Wigdahl B
    Virology; 2000 Sep; 274(2):262-77. PubMed ID: 10964770
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Identification of a Ets1 variant protein unaffected in its chromatin and in vitro DNA binding capacities by T cell antigen receptor triggering and intracellular calcium rises.
    Pognonec P; Boulukos KE; Bosselut R; Boyer C; Schmitt-Verhulst AM; Ghysdael J
    Oncogene; 1990 Apr; 5(4):603-10. PubMed ID: 2183162
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The product of the c-ets-1 proto-oncogene and the related Ets2 protein act as transcriptional activators of the long terminal repeat of human T cell leukemia virus HTLV-1.
    Bosselut R; Duvall JF; Gégonne A; Bailly M; Hémar A; Brady J; Ghysdael J
    EMBO J; 1990 Oct; 9(10):3137-44. PubMed ID: 2209540
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.